Author: Uchakin, Peter N.; Sakhalkar, Vishwas S.; Dane, Francis C.; Uchakina, Olga N.; Sheed, Jatayah N.; Uphouse, William T.; Sakhalkar, Om V.
Title: Azithromycin Reduces Markers of Vascular Damage in Pediatric Patients With Sickle Cell Disease Cord-id: f7h0c0vz Document date: 2021_7_28
ID: f7h0c0vz
Snippet: BACKGROUND: Immunomodulatory effects of macrolides in chronic inflammation are well known. In this study, we tested our hypothesis that azithromycin (AZT) can decrease inflammation in pediatric patients with sickle cell disease (SCD). METHODS: The use of AZT as an anti-inflammatory agent was evaluated in double-blind, placebo-controlled, cross-over study for 8 weeks of treatment with 8 weeks of washout. Blood samples were collected before (PRE) and after (POST) each 8-week treatment period. Repe
Document: BACKGROUND: Immunomodulatory effects of macrolides in chronic inflammation are well known. In this study, we tested our hypothesis that azithromycin (AZT) can decrease inflammation in pediatric patients with sickle cell disease (SCD). METHODS: The use of AZT as an anti-inflammatory agent was evaluated in double-blind, placebo-controlled, cross-over study for 8 weeks of treatment with 8 weeks of washout. Blood samples were collected before (PRE) and after (POST) each 8-week treatment period. Repeated measures analysis of variance (ANOVA) with post hoc multiple comparison procedures and Chi-square test were used for statistical analysis of the data. Complete blood count, distribution of the lymphocyte subsets, and plasma levels of markers of vascular damage were analyzed. RESULTS: A significant decrease in the number of leucocytes and granulocytes was observed in AZT group following treatment. An opposite dynamic was observed in placebo group; numbers of granulocytes significantly increased at POST interval. All markers of vascular damage were reduced in AZT group at POST interval with overall significance (P = 0.026). The most prominent significant changes were observed in levels of myeloid-related protein 8/14 (MRP8/14), lipocalin A (NGAL), matrix metalloproteinases (MMP) 9, and insulin-like growth factor-binding protein (IGFBP) 4. Plasma level of C-reactive protein (CRP) was significantly decreased in AZT group as well. CONCLUSIONS: Data suggested that AZT may be beneficial in management of microvascular injury in SCD.
Search related documents:
Co phrase search for related documents- acute illness and adhesion molecule: 1
- acute illness and locally spread: 1
- acute sars cov respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute sars cov respiratory syndrome coronavirus and adequate host response: 1
- acute sars cov respiratory syndrome coronavirus and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute sars cov respiratory syndrome coronavirus and local focus: 1
- acute sars cov respiratory syndrome coronavirus and local inflammatory response: 1, 2
- acute sars cov respiratory syndrome coronavirus and locally spread: 1, 2, 3, 4
- acute sars cov respiratory syndrome coronavirus and lung fibroblast: 1, 2, 3, 4, 5
- acute sars cov respiratory syndrome coronavirus and lymphocyte subset: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute sars cov respiratory syndrome coronavirus and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- adaptive innate and adhesion molecule: 1, 2, 3, 4, 5
- adaptive innate and local inflammatory response: 1
- adaptive innate and lung fibroblast: 1, 2
- adaptive innate and lymphocyte subset: 1
- adaptive innate and macrophage monocyte: 1, 2, 3, 4, 5
- adhesion molecule and local inflammatory response: 1
- adhesion molecule and macrophage monocyte: 1
Co phrase search for related documents, hyperlinks ordered by date